Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of DTPa-HBV-IPV/Hib vaccine in healthy Canadian infants
2013-003428-34Phase 4
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of DTaP-IPV-HB-Hib vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by GSK. Primary endpoint: Anti-PRP antibody concentration at least 0.15 micrograms/mL.
02
Drugs
DTaP-IPV-HB-Hib vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2013-003428-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003428-34.